文献速递药物相互作用特殊人群用药

恩杂鲁胺:理解与管理药物相互作用以提升患者安全与疗效

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy.
PubMed 文献 · Drug Saf · 2024-04-12

恩杂鲁胺是口服雄激素受体信号抑制剂,用于前列腺癌治疗。该综述汇总其药代动力学特征、特殊人群用药及与多类常用药物的相互作用,旨在为临床医生和患者提供管理药物相互作用、优化疗效与安全性的依据。

要点

  • 恩杂鲁胺是CYP2C9和CYP2C19的中度诱导剂,CYP3A4的强诱导剂。
  • 恩杂鲁胺主要经CYP3A4和CYP2C8代谢,合用经这些酶代谢的药物时需警惕相互作用。
  • 恩杂鲁胺在前列腺癌患者中还是外排转运体P-糖蛋白的轻度抑制剂。

核心结论

  • 恩杂鲁胺与多类常用药物存在相互作用,理解并管理这些相互作用有助于提高患者安全和药物疗效。

研究设计与样本

  • 综述概述了恩杂鲁胺的给药方案、特殊人群用药、药代动力学、处方信息变更及与合用药物相互作用的潜力。
  • 综述描述了恩杂鲁胺与前列腺癌患者常用多类药物的相互作用,包括口服雄激素剥夺治疗药、心血管药物、抗糖尿病药、抗抑郁药、抗癫痫药、泌尿科用药、镇痛药、质子泵抑制剂、免疫抑制剂和抗痛风药。
  • 综述还简要讨论了恩杂鲁胺与常见维生素和补充剂的相互作用。

主要发现

  • 恩杂鲁胺是CYP2C9和CYP2C19的中度诱导剂,是CYP3A4的强诱导剂。
  • 恩杂鲁胺在前列腺癌患者中显示为外排转运体P-糖蛋白的轻度抑制剂。
  • 恩杂鲁胺主要经CYP3A4和CYP2C8代谢。
  • 药物相互作用风险主要出现在恩杂鲁胺与作用于这些CYP酶(包括CYP3A4)的其他药物合用时。
  • 药物相互作用可导致其他药物体内水平异常升高或降低,也可能由其他药物改变恩杂鲁胺水平。

临床怎么用

  • 临床医生应了解恩杂鲁胺与前列腺癌患者常用多类药物的相互作用,以支持决策。
  • 管理恩杂鲁胺药物相互作用有助于提高患者安全和优化药物疗效。
  • 综述为医疗从业者和患者提供了理解和管恩杂鲁胺药物相互作用的资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also shown to be a mild inhibitor of the efflux transporter P-glycoprotein in patients with prostate cancer. Enzalutamide is primarily metabolized by CYP3A4 and CYP2C8. The risk of enzalutamide drug interactions arises primarily when it is coadministered with other drugs that interact with these CYPs, including CYP3A4. In this review, we begin by providing an overview of enzalutamide including its dosing, use in special populations, pharmacokinetics, changes to its prescribing information, and potential for interaction with coadministered drugs. Enzalutamide interactions with drugs from a wide range of medication classes commonly prescribed to patients with prostate cancer are described, including oral androgen deprivation therapy, agents used to treat a range of cardiovascular diseases, antidiabetic drugs, antidepressants, anti-seizure medications, common urology medications, analgesics, proton pump inhibitors, immunosuppressants, and antigout drugs. Enzalutamide interactions with common vitamins and supplements are also briefly discussed. This review provides a resource for healthcare practitioners and patients that will help provide a basis for the understanding and management of enzalutamide drug-drug interactions to inform decision making, improve patient safety, and optimize drug efficacy. Enzalutamide is a drug that is used to treat various stages of advanced prostate cancer, a type of cancer that begins in the prostate and may spread beyond the prostate. Enzalutamide stops testosterone from stimulating prostate cancer growth. Like other drugs, enzalutamide enters the bloodstream, and then is processed and removed from the body. Sometimes, when a person takes multiple drugs, one drug can make it difficult for the body to process and remove one or more of the other drugs. This is referred to as a drug interaction. Enzalutamide drug interactions can cause the level of other drugs in the body to increase or decrease in an abnormal way. It is also possible for certain other drugs to alter the levels of enzalutamide. Drug interactions that cause the level of a drug to get too low can prevent that drug from working effectively, whereas drug interactions that cause the level of a drug to get too high can lead to side effects of that drug. People with prostate cancer are mostly aged 65 years or older and often take medications to treat a variety of diseases. Examples include medications to treat heart conditions, diabetes, high cholesterol, high blood pressure, and many other conditions. Here, we describe enzalutamide drug interactions with these types of medications. Our goal is to provide a resource to help healthcare providers and patients better understand enzalutamide drug interactions and how to manage them to improve patient safety and drug effectiveness.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Lennep BW, Mack J, Poondru S, et al. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy. Drug Saf. 2024. PMID: 38607520. doi:10.1007/s40264-024-01415-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。